A head‐to‐head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene–related peptide for chronic and episodic migraine

Objective To compare the effectiveness and safety of galcanezumab, fremanezumab, and erenumab for the treatment of chronic and episodic migraine, through real‐world data. Background Monoclonal antibodies (mAbs) targeting the calcitonin gene–related peptide (CGRP) pathway have been tested extensively...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Headache Ročník 63; číslo 6; s. 788 - 794
Hlavní autori:	Saccà, Francesco, Braca, Simone, Sansone, Mattia, Miele, Angelo, Stornaiuolo, Antonio, De Simone, Roberto, Russo, Cinzia Valeria
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Wiley Subscription Services, Inc 01.06.2023
Predmet:	Calcitonin Calcitonin gene-related peptide Clinical trials Cohort analysis Effectiveness erenumab fremanezumab galcanezumab Headache Headaches Migraine Monoclonal antibodies Observational studies Patients Peptides Reduction Safety calcitonin gene-related peptide migraine erenumab fremanezumab galcanezumab monoclonal antibodies
ISSN:	0017-8748, 1526-4610, 1526-4610
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!